News

WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 3, 2009-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that the Company will hold a conference call at 8:00 a.m. ET on Monday, December 14, 2009, to review the clinical data reported on TAP compounds at the AACR-NCI-EORTC, American Society of Hematology, and San Antonio Breast Cancer Symposium medical meetings held in November/December 2009. This call will include comments by ImmunoGen’s Chief Executive Officer, Daniel Junius, Chief Medical Officer, James O’Leary, MD, and Chief Scientific Officer, John Lambert, PhD.

To access the live call by phone, dial 913-312-1426. Passcode is 3466172. The call also may be accessed through the Investor Information section of the Company’s website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through December 28, 2009.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen’s proprietary cancer-cell killing agents specifically to cancer targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

Source: ImmunoGen, Inc.

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations
and Corporate Communications
info@immunogen.com